nodes	percent_of_prediction	percent_of_DWPC	metapath
Fludarabine—RRM1—Hydroxyurea—head and neck cancer	0.662	0.82	CbGbCtD
Fludarabine—SLC29A1—Fluorouracil—head and neck cancer	0.145	0.18	CbGbCtD
Fludarabine—Optic nerve disorder—Fluorouracil—head and neck cancer	0.00494	0.0467	CcSEcCtD
Fludarabine—RRM1—larynx—head and neck cancer	0.0048	0.242	CbGeAlD
Fludarabine—RRM1—Fluoropyrimidine Activity—XRCC3—head and neck cancer	0.00425	0.0656	CbGpPWpGaD
Fludarabine—Skin toxicity—Docetaxel—head and neck cancer	0.00419	0.0396	CcSEcCtD
Fludarabine—SLC29A1—Fluoropyrimidine Activity—XRCC3—head and neck cancer	0.00389	0.06	CbGpPWpGaD
Fludarabine—Cerebellar syndrome—Fluorouracil—head and neck cancer	0.00333	0.0315	CcSEcCtD
Fludarabine—Fibrosis—Hydroxyurea—head and neck cancer	0.00325	0.0308	CcSEcCtD
Fludarabine—POLA1—G1/S-Specific Transcription—CCNA1—head and neck cancer	0.00319	0.0493	CbGpPWpGaD
Fludarabine—RRM1—Fluoropyrimidine Activity—DPYD—head and neck cancer	0.00283	0.0436	CbGpPWpGaD
Fludarabine—DCK—Pyrimidine metabolism—DPYD—head and neck cancer	0.00281	0.0433	CbGpPWpGaD
Fludarabine—SLC29A1—Fluoropyrimidine Activity—DPYD—head and neck cancer	0.00258	0.0399	CbGpPWpGaD
Fludarabine—Myelodysplastic syndrome—Docetaxel—head and neck cancer	0.00241	0.0228	CcSEcCtD
Fludarabine—Fibrosis—Fluorouracil—head and neck cancer	0.00234	0.0221	CcSEcCtD
Fludarabine—Myelosuppression—Vinblastine—head and neck cancer	0.00217	0.0206	CcSEcCtD
Fludarabine—Pulmonary fibrosis—Hydroxyurea—head and neck cancer	0.00211	0.02	CcSEcCtD
Fludarabine—RRM1—Fluoropyrimidine Activity—SMUG1—head and neck cancer	0.00201	0.031	CbGpPWpGaD
Fludarabine—RRM1—E2F transcription factor network—CEBPA—head and neck cancer	0.00201	0.031	CbGpPWpGaD
Fludarabine—Flavin adenine dinucleotide—DPYD—head and neck cancer	0.002	0.675	CrCbGaD
Fludarabine—Lung infiltration—Hydroxyurea—head and neck cancer	0.00198	0.0187	CcSEcCtD
Fludarabine—Myelosuppression—Hydroxyurea—head and neck cancer	0.00198	0.0187	CcSEcCtD
Fludarabine—RRM1—hair follicle—head and neck cancer	0.0019	0.0958	CbGeAlD
Fludarabine—POLA1—E2F mediated regulation of DNA replication—CCNA1—head and neck cancer	0.00188	0.029	CbGpPWpGaD
Fludarabine—SLC29A1—Fluoropyrimidine Activity—SMUG1—head and neck cancer	0.00184	0.0284	CbGpPWpGaD
Fludarabine—Mucosal inflammation—Hydroxyurea—head and neck cancer	0.00168	0.0159	CcSEcCtD
Fludarabine—RRM1—E2F transcription factor network—XRCC1—head and neck cancer	0.00164	0.0252	CbGpPWpGaD
Fludarabine—RRM1—Fluoropyrimidine Activity—TYMS—head and neck cancer	0.00161	0.0248	CbGpPWpGaD
Fludarabine—DCK—Pyrimidine metabolism—TYMS—head and neck cancer	0.0016	0.0247	CbGpPWpGaD
Fludarabine—POLA1—G1/S-Specific Transcription—TYMS—head and neck cancer	0.00154	0.0238	CbGpPWpGaD
Fludarabine—SLC29A1—Fluoropyrimidine Activity—TYMS—head and neck cancer	0.00147	0.0227	CbGpPWpGaD
Fludarabine—Myelosuppression—Fluorouracil—head and neck cancer	0.00143	0.0135	CcSEcCtD
Fludarabine—RRM1—Nucleotide metabolism—DPYD—head and neck cancer	0.00142	0.0219	CbGpPWpGaD
Fludarabine—Digestion impaired—Hydroxyurea—head and neck cancer	0.00139	0.0131	CcSEcCtD
Fludarabine—Bone marrow depression—Hydroxyurea—head and neck cancer	0.00138	0.013	CcSEcCtD
Fludarabine—SLC28A3—trachea—head and neck cancer	0.00137	0.0693	CbGeAlD
Fludarabine—POLA1—parotid gland—head and neck cancer	0.00131	0.0659	CbGeAlD
Fludarabine—Neurotoxicity—Docetaxel—head and neck cancer	0.00124	0.0118	CcSEcCtD
Fludarabine—Numbness—Vinblastine—head and neck cancer	0.00123	0.0116	CcSEcCtD
Fludarabine—Pericardial effusion—Docetaxel—head and neck cancer	0.00118	0.0111	CcSEcCtD
Fludarabine—Sensory loss—Vinblastine—head and neck cancer	0.00118	0.0111	CcSEcCtD
Fludarabine—DCK—Purine metabolism—GPX1—head and neck cancer	0.00117	0.0181	CbGpPWpGaD
Fludarabine—POLA1—E2F transcription factor network—CEBPA—head and neck cancer	0.00113	0.0174	CbGpPWpGaD
Fludarabine—Pulmonary fibrosis—Docetaxel—head and neck cancer	0.0011	0.0104	CcSEcCtD
Fludarabine—DCK—Nucleotide metabolism—DPYD—head and neck cancer	0.00109	0.0169	CbGpPWpGaD
Fludarabine—Myelosuppression—Docetaxel—head and neck cancer	0.00103	0.00974	CcSEcCtD
Fludarabine—Hyperuricaemia—Hydroxyurea—head and neck cancer	0.001	0.00947	CcSEcCtD
Fludarabine—Adenosine triphosphate—AKT1—head and neck cancer	0.000963	0.325	CrCbGaD
Fludarabine—Blood uric acid increased—Hydroxyurea—head and neck cancer	0.000946	0.00895	CcSEcCtD
Fludarabine—POLA1—E2F transcription factor network—XRCC1—head and neck cancer	0.000922	0.0142	CbGpPWpGaD
Fludarabine—POLA1—E2F mediated regulation of DNA replication—TYMS—head and neck cancer	0.000907	0.014	CbGpPWpGaD
Fludarabine—Mucosal inflammation—Docetaxel—head and neck cancer	0.000872	0.00825	CcSEcCtD
Fludarabine—Phlebitis—Vinblastine—head and neck cancer	0.000858	0.00812	CcSEcCtD
Fludarabine—RRM1—E2F transcription factor network—TYMS—head and neck cancer	0.000853	0.0132	CbGpPWpGaD
Fludarabine—Deafness—Vinblastine—head and neck cancer	0.000827	0.00782	CcSEcCtD
Fludarabine—RRM1—Nucleotide metabolism—TYMS—head and neck cancer	0.000809	0.0125	CbGpPWpGaD
Fludarabine—Numbness—Fluorouracil—head and neck cancer	0.000807	0.00763	CcSEcCtD
Fludarabine—DCK—parotid gland—head and neck cancer	0.000806	0.0406	CbGeAlD
Fludarabine—POLA1—Synthesis of DNA—CCNA1—head and neck cancer	0.0008	0.0123	CbGpPWpGaD
Fludarabine—Deep vein thrombosis—Docetaxel—head and neck cancer	0.000793	0.00751	CcSEcCtD
Fludarabine—Sensory loss—Fluorouracil—head and neck cancer	0.000772	0.0073	CcSEcCtD
Fludarabine—DCK—saliva-secreting gland—head and neck cancer	0.000772	0.0389	CbGeAlD
Fludarabine—RRM1—Nucleotide metabolism—GPX1—head and neck cancer	0.000766	0.0118	CbGpPWpGaD
Fludarabine—POLA1—thyroid gland—head and neck cancer	0.000764	0.0385	CbGeAlD
Fludarabine—Cerebrovascular accident—Vinblastine—head and neck cancer	0.000755	0.00714	CcSEcCtD
Fludarabine—Hepatic failure—Hydroxyurea—head and neck cancer	0.00075	0.0071	CcSEcCtD
Fludarabine—POLA1—DNA Replication—CCNA1—head and neck cancer	0.00075	0.0116	CbGpPWpGaD
Fludarabine—SLC29A1—connective tissue—head and neck cancer	0.000742	0.0374	CbGeAlD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—TYMS—head and neck cancer	0.000741	0.0114	CbGpPWpGaD
Fludarabine—Supraventricular tachycardia—Docetaxel—head and neck cancer	0.000737	0.00697	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—RARB—head and neck cancer	0.000723	0.0112	CbGpPWpGaD
Fludarabine—POLA1—G1/S Transition—CCNA1—head and neck cancer	0.000722	0.0111	CbGpPWpGaD
Fludarabine—Haemoglobin decreased—Docetaxel—head and neck cancer	0.000701	0.00664	CcSEcCtD
Fludarabine—RRM1—lymphoid tissue—head and neck cancer	0.000667	0.0337	CbGeAlD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—RAD51—head and neck cancer	0.000658	0.0102	CbGpPWpGaD
Fludarabine—POLA1—S Phase—CCNA1—head and neck cancer	0.000656	0.0101	CbGpPWpGaD
Fludarabine—SLC29A1—trachea—head and neck cancer	0.000623	0.0314	CbGeAlD
Fludarabine—Angina pectoris—Vinblastine—head and neck cancer	0.000623	0.00589	CcSEcCtD
Fludarabine—DCK—Nucleotide metabolism—TYMS—head and neck cancer	0.000623	0.0096	CbGpPWpGaD
Fludarabine—Coma—Fluorouracil—head and neck cancer	0.000611	0.00578	CcSEcCtD
Fludarabine—Oesophagitis—Fluorouracil—head and neck cancer	0.000611	0.00578	CcSEcCtD
Fludarabine—POLA1—Mitotic G1-G1/S phases—CCNA1—head and neck cancer	0.000609	0.00939	CbGpPWpGaD
Fludarabine—Pancytopenia—Vinblastine—head and neck cancer	0.000607	0.00574	CcSEcCtD
Fludarabine—RRM1—thyroid gland—head and neck cancer	0.000606	0.0306	CbGeAlD
Fludarabine—DCK—trachea—head and neck cancer	0.000595	0.03	CbGeAlD
Fludarabine—DCK—Nucleotide metabolism—GPX1—head and neck cancer	0.000589	0.00909	CbGpPWpGaD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—TYMS—head and neck cancer	0.00057	0.0088	CbGpPWpGaD
Fludarabine—Acute coronary syndrome—Vinblastine—head and neck cancer	0.000562	0.00531	CcSEcCtD
Fludarabine—Myocardial infarction—Vinblastine—head and neck cancer	0.000559	0.00528	CcSEcCtD
Fludarabine—Neuropathy peripheral—Vinblastine—head and neck cancer	0.000559	0.00528	CcSEcCtD
Fludarabine—Pancytopenia—Hydroxyurea—head and neck cancer	0.000554	0.00524	CcSEcCtD
Fludarabine—Dysuria—Hydroxyurea—head and neck cancer	0.000545	0.00516	CcSEcCtD
Fludarabine—Neutropenia—Hydroxyurea—head and neck cancer	0.000545	0.00516	CcSEcCtD
Fludarabine—SLC29A1—lymphoid tissue—head and neck cancer	0.000543	0.0274	CbGeAlD
Fludarabine—RRM1—head—head and neck cancer	0.000538	0.0271	CbGeAlD
Fludarabine—RRM1—Fluoropyrimidine Activity—TP53—head and neck cancer	0.000534	0.00824	CbGpPWpGaD
Fludarabine—DCK—lymphoid tissue—head and neck cancer	0.000518	0.0262	CbGeAlD
Fludarabine—Haemoglobin—Vinblastine—head and neck cancer	0.000514	0.00486	CcSEcCtD
Fludarabine—Haemorrhage—Vinblastine—head and neck cancer	0.000512	0.00484	CcSEcCtD
Fludarabine—Neuropathy peripheral—Hydroxyurea—head and neck cancer	0.000509	0.00482	CcSEcCtD
Fludarabine—Hypoaesthesia—Vinblastine—head and neck cancer	0.000509	0.00482	CcSEcCtD
Fludarabine—Pharyngitis—Vinblastine—head and neck cancer	0.000508	0.0048	CcSEcCtD
Fludarabine—Hearing impaired—Docetaxel—head and neck cancer	0.000507	0.0048	CcSEcCtD
Fludarabine—Stomatitis—Hydroxyurea—head and neck cancer	0.000507	0.00479	CcSEcCtD
Fludarabine—Cardiac failure—Fluorouracil—head and neck cancer	0.000497	0.00471	CcSEcCtD
Fludarabine—SLC29A1—thyroid gland—head and neck cancer	0.000493	0.0249	CbGeAlD
Fludarabine—Respiratory failure—Docetaxel—head and neck cancer	0.000492	0.00465	CcSEcCtD
Fludarabine—SLC29A1—Fluoropyrimidine Activity—TP53—head and neck cancer	0.000488	0.00753	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.000487	0.00752	CbGpPWpGaD
Fludarabine—Gastrointestinal haemorrhage—Fluorouracil—head and neck cancer	0.000485	0.00459	CcSEcCtD
Fludarabine—POLA1—E2F transcription factor network—TYMS—head and neck cancer	0.00048	0.00741	CbGpPWpGaD
Fludarabine—POLA1—lymph node—head and neck cancer	0.000474	0.0239	CbGeAlD
Fludarabine—DCK—thyroid gland—head and neck cancer	0.000471	0.0238	CbGeAlD
Fludarabine—Haemoglobin—Hydroxyurea—head and neck cancer	0.000469	0.00444	CcSEcCtD
Fludarabine—Haemorrhage—Hydroxyurea—head and neck cancer	0.000467	0.00441	CcSEcCtD
Fludarabine—Alopecia—Vinblastine—head and neck cancer	0.000452	0.00428	CcSEcCtD
Fludarabine—Oesophagitis—Docetaxel—head and neck cancer	0.000441	0.00417	CcSEcCtD
Fludarabine—SLC29A1—head—head and neck cancer	0.000437	0.0221	CbGeAlD
Fludarabine—Dysphagia—Fluorouracil—head and neck cancer	0.00042	0.00397	CcSEcCtD
Fludarabine—Chills—Hydroxyurea—head and neck cancer	0.000419	0.00396	CcSEcCtD
Fludarabine—DCK—head—head and neck cancer	0.000418	0.0211	CbGeAlD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—TYMS—head and neck cancer	0.000418	0.00644	CbGpPWpGaD
Fludarabine—Ill-defined disorder—Vinblastine—head and neck cancer	0.000413	0.00391	CcSEcCtD
Fludarabine—Alopecia—Hydroxyurea—head and neck cancer	0.000412	0.0039	CcSEcCtD
Fludarabine—Anaemia—Vinblastine—head and neck cancer	0.000412	0.00389	CcSEcCtD
Fludarabine—Angina pectoris—Fluorouracil—head and neck cancer	0.000409	0.00387	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—RARB—head and neck cancer	0.000407	0.00628	CbGpPWpGaD
Fludarabine—Phlebitis—Docetaxel—head and neck cancer	0.000407	0.00385	CcSEcCtD
Fludarabine—Malaise—Vinblastine—head and neck cancer	0.000402	0.0038	CcSEcCtD
Fludarabine—Leukopenia—Vinblastine—head and neck cancer	0.000399	0.00377	CcSEcCtD
Fludarabine—Pancytopenia—Fluorouracil—head and neck cancer	0.000398	0.00377	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—TYMS—head and neck cancer	0.000395	0.0061	CbGpPWpGaD
Fludarabine—Deafness—Docetaxel—head and neck cancer	0.000392	0.00371	CcSEcCtD
Fludarabine—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.00039	0.00369	CcSEcCtD
Fludarabine—Hepatic failure—Docetaxel—head and neck cancer	0.00039	0.00369	CcSEcCtD
Fludarabine—Cardiac failure congestive—Docetaxel—head and neck cancer	0.000386	0.00365	CcSEcCtD
Fludarabine—Convulsion—Vinblastine—head and neck cancer	0.000386	0.00365	CcSEcCtD
Fludarabine—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.000377	0.00357	CcSEcCtD
Fludarabine—RRM1—lymph node—head and neck cancer	0.000377	0.019	CbGeAlD
Fludarabine—Pneumonia—Fluorouracil—head and neck cancer	0.000376	0.00356	CcSEcCtD
Fludarabine—Anaemia—Hydroxyurea—head and neck cancer	0.000375	0.00355	CcSEcCtD
Fludarabine—Discomfort—Vinblastine—head and neck cancer	0.000375	0.00354	CcSEcCtD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—CCND1—head and neck cancer	0.000373	0.00576	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—RAD51—head and neck cancer	0.000371	0.00572	CbGpPWpGaD
Fludarabine—Visual disturbance—Docetaxel—head and neck cancer	0.00037	0.0035	CcSEcCtD
Fludarabine—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.000369	0.00349	CcSEcCtD
Fludarabine—Neuropathy peripheral—Fluorouracil—head and neck cancer	0.000367	0.00347	CcSEcCtD
Fludarabine—Myocardial infarction—Fluorouracil—head and neck cancer	0.000367	0.00347	CcSEcCtD
Fludarabine—Malaise—Hydroxyurea—head and neck cancer	0.000366	0.00346	CcSEcCtD
Fludarabine—Stomatitis—Fluorouracil—head and neck cancer	0.000365	0.00345	CcSEcCtD
Fludarabine—Urinary tract infection—Fluorouracil—head and neck cancer	0.000364	0.00344	CcSEcCtD
Fludarabine—Leukopenia—Hydroxyurea—head and neck cancer	0.000364	0.00344	CcSEcCtD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.000363	0.0056	CbGpPWpGaD
Fludarabine—Cardiac failure—Docetaxel—head and neck cancer	0.000359	0.0034	CcSEcCtD
Fludarabine—Thrombocytopenia—Vinblastine—head and neck cancer	0.000356	0.00337	CcSEcCtD
Fludarabine—RRM1—Metabolism—UROD—head and neck cancer	0.000354	0.00546	CbGpPWpGaD
Fludarabine—Epistaxis—Fluorouracil—head and neck cancer	0.000353	0.00334	CcSEcCtD
Fludarabine—Convulsion—Hydroxyurea—head and neck cancer	0.000352	0.00333	CcSEcCtD
Fludarabine—Sinusitis—Fluorouracil—head and neck cancer	0.000351	0.00332	CcSEcCtD
Fludarabine—Gastrointestinal haemorrhage—Docetaxel—head and neck cancer	0.00035	0.00331	CcSEcCtD
Fludarabine—POLA1—G1/S Transition—TYMS—head and neck cancer	0.000349	0.00538	CbGpPWpGaD
Fludarabine—Anorexia—Vinblastine—head and neck cancer	0.000346	0.00328	CcSEcCtD
Fludarabine—Discomfort—Hydroxyurea—head and neck cancer	0.000342	0.00323	CcSEcCtD
Fludarabine—Haemoglobin—Fluorouracil—head and neck cancer	0.000338	0.00319	CcSEcCtD
Fludarabine—Haemorrhage—Fluorouracil—head and neck cancer	0.000336	0.00318	CcSEcCtD
Fludarabine—Hypoaesthesia—Fluorouracil—head and neck cancer	0.000334	0.00316	CcSEcCtD
Fludarabine—Pharyngitis—Fluorouracil—head and neck cancer	0.000333	0.00315	CcSEcCtD
Fludarabine—Oedema—Hydroxyurea—head and neck cancer	0.000331	0.00314	CcSEcCtD
Fludarabine—Infection—Hydroxyurea—head and neck cancer	0.000329	0.00312	CcSEcCtD
Fludarabine—Paraesthesia—Vinblastine—head and neck cancer	0.000326	0.00309	CcSEcCtD
Fludarabine—Dehydration—Docetaxel—head and neck cancer	0.000326	0.00308	CcSEcCtD
Fludarabine—Nervous system disorder—Hydroxyurea—head and neck cancer	0.000325	0.00308	CcSEcCtD
Fludarabine—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.000325	0.00307	CcSEcCtD
Fludarabine—Liver function test abnormal—Docetaxel—head and neck cancer	0.000323	0.00306	CcSEcCtD
Fludarabine—Anorexia—Hydroxyurea—head and neck cancer	0.000316	0.00299	CcSEcCtD
Fludarabine—Decreased appetite—Vinblastine—head and neck cancer	0.000316	0.00299	CcSEcCtD
Fludarabine—Toxic epidermal necrolysis—Docetaxel—head and neck cancer	0.000315	0.00298	CcSEcCtD
Fludarabine—Constipation—Vinblastine—head and neck cancer	0.000311	0.00294	CcSEcCtD
Fludarabine—Pain—Vinblastine—head and neck cancer	0.000311	0.00294	CcSEcCtD
Fludarabine—SLC29A1—lymph node—head and neck cancer	0.000306	0.0154	CbGeAlD
Fludarabine—Dysphagia—Docetaxel—head and neck cancer	0.000303	0.00286	CcSEcCtD
Fludarabine—Arrhythmia—Fluorouracil—head and neck cancer	0.0003	0.00284	CcSEcCtD
Fludarabine—Feeling abnormal—Vinblastine—head and neck cancer	0.0003	0.00283	CcSEcCtD
Fludarabine—Alopecia—Fluorouracil—head and neck cancer	0.000297	0.00281	CcSEcCtD
Fludarabine—Dyspnoea—Hydroxyurea—head and neck cancer	0.000296	0.0028	CcSEcCtD
Fludarabine—Angina pectoris—Docetaxel—head and neck cancer	0.000295	0.00279	CcSEcCtD
Fludarabine—POLA1—Mitotic G1-G1/S phases—TYMS—head and neck cancer	0.000294	0.00453	CbGpPWpGaD
Fludarabine—DCK—lymph node—head and neck cancer	0.000293	0.0148	CbGeAlD
Fludarabine—Dyspepsia—Hydroxyurea—head and neck cancer	0.000292	0.00276	CcSEcCtD
Fludarabine—Decreased appetite—Hydroxyurea—head and neck cancer	0.000288	0.00273	CcSEcCtD
Fludarabine—Pancytopenia—Docetaxel—head and neck cancer	0.000288	0.00272	CcSEcCtD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—CCND1—head and neck cancer	0.000287	0.00443	CbGpPWpGaD
Fludarabine—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.000286	0.00271	CcSEcCtD
Fludarabine—Fatigue—Hydroxyurea—head and neck cancer	0.000286	0.0027	CcSEcCtD
Fludarabine—Pain—Hydroxyurea—head and neck cancer	0.000283	0.00268	CcSEcCtD
Fludarabine—Constipation—Hydroxyurea—head and neck cancer	0.000283	0.00268	CcSEcCtD
Fludarabine—Neutropenia—Docetaxel—head and neck cancer	0.000283	0.00268	CcSEcCtD
Fludarabine—Feeling abnormal—Hydroxyurea—head and neck cancer	0.000273	0.00258	CcSEcCtD
Fludarabine—DCK—Metabolism—UROD—head and neck cancer	0.000273	0.0042	CbGpPWpGaD
Fludarabine—Pneumonia—Docetaxel—head and neck cancer	0.000272	0.00257	CcSEcCtD
Fludarabine—Anaemia—Fluorouracil—head and neck cancer	0.00027	0.00256	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—CASP8—head and neck cancer	0.00027	0.00417	CbGpPWpGaD
Fludarabine—Hypersensitivity—Vinblastine—head and neck cancer	0.000268	0.00253	CcSEcCtD
Fludarabine—Stevens-Johnson syndrome—Docetaxel—head and neck cancer	0.000268	0.00253	CcSEcCtD
Fludarabine—Acute coronary syndrome—Docetaxel—head and neck cancer	0.000266	0.00252	CcSEcCtD
Fludarabine—Renal failure—Docetaxel—head and neck cancer	0.000265	0.00251	CcSEcCtD
Fludarabine—Neuropathy peripheral—Docetaxel—head and neck cancer	0.000265	0.0025	CcSEcCtD
Fludarabine—Myocardial infarction—Docetaxel—head and neck cancer	0.000265	0.0025	CcSEcCtD
Fludarabine—Stomatitis—Docetaxel—head and neck cancer	0.000263	0.00249	CcSEcCtD
Fludarabine—Body temperature increased—Hydroxyurea—head and neck cancer	0.000262	0.00248	CcSEcCtD
Fludarabine—Leukopenia—Fluorouracil—head and neck cancer	0.000262	0.00248	CcSEcCtD
Fludarabine—Asthenia—Vinblastine—head and neck cancer	0.000261	0.00247	CcSEcCtD
Fludarabine—Epistaxis—Docetaxel—head and neck cancer	0.000255	0.00241	CcSEcCtD
Fludarabine—Convulsion—Fluorouracil—head and neck cancer	0.000253	0.0024	CcSEcCtD
Fludarabine—Myalgia—Fluorouracil—head and neck cancer	0.000249	0.00235	CcSEcCtD
Fludarabine—Diarrhoea—Vinblastine—head and neck cancer	0.000249	0.00235	CcSEcCtD
Fludarabine—Discomfort—Fluorouracil—head and neck cancer	0.000246	0.00233	CcSEcCtD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—TP53—head and neck cancer	0.000246	0.00379	CbGpPWpGaD
Fludarabine—Hypersensitivity—Hydroxyurea—head and neck cancer	0.000244	0.00231	CcSEcCtD
Fludarabine—Haemoglobin—Docetaxel—head and neck cancer	0.000244	0.0023	CcSEcCtD
Fludarabine—Haemorrhage—Docetaxel—head and neck cancer	0.000242	0.00229	CcSEcCtD
Fludarabine—Hypoaesthesia—Docetaxel—head and neck cancer	0.000241	0.00228	CcSEcCtD
Fludarabine—Confusional state—Fluorouracil—head and neck cancer	0.000241	0.00228	CcSEcCtD
Fludarabine—Pharyngitis—Docetaxel—head and neck cancer	0.000241	0.00228	CcSEcCtD
Fludarabine—Anaphylactic shock—Fluorouracil—head and neck cancer	0.000239	0.00226	CcSEcCtD
Fludarabine—Oedema—Fluorouracil—head and neck cancer	0.000239	0.00226	CcSEcCtD
Fludarabine—Asthenia—Hydroxyurea—head and neck cancer	0.000238	0.00225	CcSEcCtD
Fludarabine—Infection—Fluorouracil—head and neck cancer	0.000237	0.00224	CcSEcCtD
Fludarabine—Nervous system disorder—Fluorouracil—head and neck cancer	0.000234	0.00221	CcSEcCtD
Fludarabine—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000234	0.00221	CcSEcCtD
Fludarabine—Visual impairment—Docetaxel—head and neck cancer	0.000234	0.00221	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—BCL2—head and neck cancer	0.000232	0.00358	CbGpPWpGaD
Fludarabine—Vomiting—Vinblastine—head and neck cancer	0.000231	0.00219	CcSEcCtD
Fludarabine—Erythema multiforme—Docetaxel—head and neck cancer	0.000229	0.00217	CcSEcCtD
Fludarabine—Headache—Vinblastine—head and neck cancer	0.000228	0.00215	CcSEcCtD
Fludarabine—Anorexia—Fluorouracil—head and neck cancer	0.000227	0.00215	CcSEcCtD
Fludarabine—Diarrhoea—Hydroxyurea—head and neck cancer	0.000227	0.00215	CcSEcCtD
Fludarabine—POLA1—Cell Cycle, Mitotic—CCNA1—head and neck cancer	0.000223	0.00344	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—TYMS—head and neck cancer	0.000223	0.00343	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—PTGS2—head and neck cancer	0.00022	0.0034	CbGpPWpGaD
Fludarabine—Chills—Docetaxel—head and neck cancer	0.000217	0.00206	CcSEcCtD
Fludarabine—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.000217	0.00206	CcSEcCtD
Fludarabine—Arrhythmia—Docetaxel—head and neck cancer	0.000217	0.00205	CcSEcCtD
Fludarabine—Nausea—Vinblastine—head and neck cancer	0.000216	0.00204	CcSEcCtD
Fludarabine—Paraesthesia—Fluorouracil—head and neck cancer	0.000214	0.00203	CcSEcCtD
Fludarabine—Alopecia—Docetaxel—head and neck cancer	0.000214	0.00203	CcSEcCtD
Fludarabine—Dyspnoea—Fluorouracil—head and neck cancer	0.000213	0.00201	CcSEcCtD
Fludarabine—Malnutrition—Docetaxel—head and neck cancer	0.000211	0.002	CcSEcCtD
Fludarabine—Vomiting—Hydroxyurea—head and neck cancer	0.000211	0.00199	CcSEcCtD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—CCND1—head and neck cancer	0.00021	0.00324	CbGpPWpGaD
Fludarabine—Dyspepsia—Fluorouracil—head and neck cancer	0.00021	0.00199	CcSEcCtD
Fludarabine—Rash—Hydroxyurea—head and neck cancer	0.000209	0.00198	CcSEcCtD
Fludarabine—Dermatitis—Hydroxyurea—head and neck cancer	0.000209	0.00198	CcSEcCtD
Fludarabine—Headache—Hydroxyurea—head and neck cancer	0.000208	0.00196	CcSEcCtD
Fludarabine—Decreased appetite—Fluorouracil—head and neck cancer	0.000207	0.00196	CcSEcCtD
Fludarabine—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000206	0.00195	CcSEcCtD
Fludarabine—Pain—Fluorouracil—head and neck cancer	0.000204	0.00193	CcSEcCtD
Fludarabine—POLA1—Cell Cycle—CCNA1—head and neck cancer	0.0002	0.00308	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—CCND1—head and neck cancer	0.000199	0.00307	CbGpPWpGaD
Fludarabine—Nausea—Hydroxyurea—head and neck cancer	0.000197	0.00186	CcSEcCtD
Fludarabine—Feeling abnormal—Fluorouracil—head and neck cancer	0.000197	0.00186	CcSEcCtD
Fludarabine—Anaemia—Docetaxel—head and neck cancer	0.000195	0.00184	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—PTEN—head and neck cancer	0.000192	0.00296	CbGpPWpGaD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—TP53—head and neck cancer	0.000189	0.00292	CbGpPWpGaD
Fludarabine—Leukopenia—Docetaxel—head and neck cancer	0.000189	0.00179	CcSEcCtD
Fludarabine—Body temperature increased—Fluorouracil—head and neck cancer	0.000189	0.00178	CcSEcCtD
Fludarabine—Cough—Docetaxel—head and neck cancer	0.000184	0.00174	CcSEcCtD
Fludarabine—Convulsion—Docetaxel—head and neck cancer	0.000183	0.00173	CcSEcCtD
Fludarabine—Myalgia—Docetaxel—head and neck cancer	0.00018	0.0017	CcSEcCtD
Fludarabine—Arthralgia—Docetaxel—head and neck cancer	0.00018	0.0017	CcSEcCtD
Fludarabine—Hypersensitivity—Fluorouracil—head and neck cancer	0.000176	0.00166	CcSEcCtD
Fludarabine—Confusional state—Docetaxel—head and neck cancer	0.000174	0.00164	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—VEGFA—head and neck cancer	0.000173	0.00268	CbGpPWpGaD
Fludarabine—Oedema—Docetaxel—head and neck cancer	0.000172	0.00163	CcSEcCtD
Fludarabine—Anaphylactic shock—Docetaxel—head and neck cancer	0.000172	0.00163	CcSEcCtD
Fludarabine—Infection—Docetaxel—head and neck cancer	0.000171	0.00162	CcSEcCtD
Fludarabine—Nervous system disorder—Docetaxel—head and neck cancer	0.000169	0.0016	CcSEcCtD
Fludarabine—Pruritus—Fluorouracil—head and neck cancer	0.000169	0.0016	CcSEcCtD
Fludarabine—Thrombocytopenia—Docetaxel—head and neck cancer	0.000169	0.0016	CcSEcCtD
Fludarabine—Anorexia—Docetaxel—head and neck cancer	0.000164	0.00155	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—MAPK3—head and neck cancer	0.000164	0.00253	CbGpPWpGaD
Fludarabine—Diarrhoea—Fluorouracil—head and neck cancer	0.000163	0.00154	CcSEcCtD
Fludarabine—POLA1—Cell Cycle—RAD51—head and neck cancer	0.00016	0.00248	CbGpPWpGaD
Fludarabine—POLA1—S Phase—CCND1—head and neck cancer	0.000159	0.00246	CbGpPWpGaD
Fludarabine—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000157	0.00148	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—MAPK1—head and neck cancer	0.000156	0.00241	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—EGFR—head and neck cancer	0.000156	0.00241	CbGpPWpGaD
Fludarabine—Paraesthesia—Docetaxel—head and neck cancer	0.000155	0.00146	CcSEcCtD
Fludarabine—Dyspnoea—Docetaxel—head and neck cancer	0.000154	0.00145	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—CASP8—head and neck cancer	0.000152	0.00235	CbGpPWpGaD
Fludarabine—Vomiting—Fluorouracil—head and neck cancer	0.000152	0.00144	CcSEcCtD
Fludarabine—Dyspepsia—Docetaxel—head and neck cancer	0.000152	0.00143	CcSEcCtD
Fludarabine—Rash—Fluorouracil—head and neck cancer	0.00015	0.00142	CcSEcCtD
Fludarabine—Dermatitis—Fluorouracil—head and neck cancer	0.00015	0.00142	CcSEcCtD
Fludarabine—Decreased appetite—Docetaxel—head and neck cancer	0.00015	0.00142	CcSEcCtD
Fludarabine—Headache—Fluorouracil—head and neck cancer	0.000149	0.00141	CcSEcCtD
Fludarabine—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000149	0.00141	CcSEcCtD
Fludarabine—Fatigue—Docetaxel—head and neck cancer	0.000148	0.0014	CcSEcCtD
Fludarabine—POLA1—Mitotic G1-G1/S phases—CCND1—head and neck cancer	0.000148	0.00228	CbGpPWpGaD
Fludarabine—Constipation—Docetaxel—head and neck cancer	0.000147	0.00139	CcSEcCtD
Fludarabine—Pain—Docetaxel—head and neck cancer	0.000147	0.00139	CcSEcCtD
Fludarabine—RRM1—Metabolism—NAT2—head and neck cancer	0.000147	0.00227	CbGpPWpGaD
Fludarabine—Feeling abnormal—Docetaxel—head and neck cancer	0.000142	0.00134	CcSEcCtD
Fludarabine—Nausea—Fluorouracil—head and neck cancer	0.000142	0.00134	CcSEcCtD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—TP53—head and neck cancer	0.000138	0.00214	CbGpPWpGaD
Fludarabine—Body temperature increased—Docetaxel—head and neck cancer	0.000136	0.00129	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	0.000135	0.00209	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	0.000131	0.00202	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—BCL2—head and neck cancer	0.000131	0.00201	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—DPYD—head and neck cancer	0.000129	0.00199	CbGpPWpGaD
Fludarabine—Hypersensitivity—Docetaxel—head and neck cancer	0.000127	0.0012	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—PTGS2—head and neck cancer	0.000124	0.00191	CbGpPWpGaD
Fludarabine—Asthenia—Docetaxel—head and neck cancer	0.000124	0.00117	CcSEcCtD
Fludarabine—RRM1—Metabolism—YAP1—head and neck cancer	0.000122	0.00189	CbGpPWpGaD
Fludarabine—Pruritus—Docetaxel—head and neck cancer	0.000122	0.00115	CcSEcCtD
Fludarabine—Diarrhoea—Docetaxel—head and neck cancer	0.000118	0.00111	CcSEcCtD
Fludarabine—DCK—Metabolism—NAT2—head and neck cancer	0.000113	0.00175	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—CCND1—head and neck cancer	0.000112	0.00173	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	0.000111	0.00171	CbGpPWpGaD
Fludarabine—Vomiting—Docetaxel—head and neck cancer	0.000109	0.00104	CcSEcCtD
Fludarabine—Rash—Docetaxel—head and neck cancer	0.000109	0.00103	CcSEcCtD
Fludarabine—Dermatitis—Docetaxel—head and neck cancer	0.000108	0.00103	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—PTEN—head and neck cancer	0.000108	0.00167	CbGpPWpGaD
Fludarabine—Headache—Docetaxel—head and neck cancer	0.000108	0.00102	CcSEcCtD
Fludarabine—POLA1—Cell Cycle, Mitotic—TYMS—head and neck cancer	0.000108	0.00166	CbGpPWpGaD
Fludarabine—Nausea—Docetaxel—head and neck cancer	0.000102	0.000968	CcSEcCtD
Fludarabine—DCK—Metabolism—DPYD—head and neck cancer	9.92e-05	0.00153	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—VEGFA—head and neck cancer	9.77e-05	0.00151	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—TYMS—head and neck cancer	9.63e-05	0.00149	CbGpPWpGaD
Fludarabine—DCK—Metabolism—YAP1—head and neck cancer	9.42e-05	0.00145	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—MAPK3—head and neck cancer	9.24e-05	0.00143	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—MAPK1—head and neck cancer	8.79e-05	0.00136	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—EGFR—head and neck cancer	8.79e-05	0.00136	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	7.63e-05	0.00118	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	7.38e-05	0.00114	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—TYMS—head and neck cancer	7.35e-05	0.00113	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—GSTM1—head and neck cancer	7.26e-05	0.00112	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—GPX1—head and neck cancer	6.96e-05	0.00107	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—CYP1A1—head and neck cancer	6.89e-05	0.00106	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	6.23e-05	0.000962	CbGpPWpGaD
Fludarabine—POLA1—Mitotic M-M/G1 phases—MAPK3—head and neck cancer	5.98e-05	0.000923	CbGpPWpGaD
Fludarabine—POLA1—Mitotic M-M/G1 phases—MAPK1—head and neck cancer	5.69e-05	0.000878	CbGpPWpGaD
Fludarabine—DCK—Metabolism—TYMS—head and neck cancer	5.66e-05	0.000872	CbGpPWpGaD
Fludarabine—DCK—Metabolism—GSTM1—head and neck cancer	5.59e-05	0.000862	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—CCND1—head and neck cancer	5.43e-05	0.000837	CbGpPWpGaD
Fludarabine—DCK—Metabolism—GPX1—head and neck cancer	5.35e-05	0.000826	CbGpPWpGaD
Fludarabine—DCK—Metabolism—CYP1A1—head and neck cancer	5.3e-05	0.000817	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—CCND1—head and neck cancer	4.85e-05	0.000748	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—MAPK3—head and neck cancer	4.47e-05	0.00069	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—MAPK1—head and neck cancer	4.26e-05	0.000657	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PTGS2—head and neck cancer	4.1e-05	0.000632	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—MAPK3—head and neck cancer	4e-05	0.000617	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—MAPK1—head and neck cancer	3.81e-05	0.000587	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PTEN—head and neck cancer	3.57e-05	0.000551	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—TP53—head and neck cancer	3.2e-05	0.000493	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PTGS2—head and neck cancer	3.15e-05	0.000486	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PTEN—head and neck cancer	2.75e-05	0.000424	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PIK3CA—head and neck cancer	2.52e-05	0.000389	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—AKT1—head and neck cancer	2.06e-05	0.000318	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PIK3CA—head and neck cancer	1.94e-05	0.000299	CbGpPWpGaD
Fludarabine—DCK—Metabolism—AKT1—head and neck cancer	1.58e-05	0.000244	CbGpPWpGaD
